Xeris Biopharma Holdings, Inc. announced the appointment of Dr. Anh Nguyen as its new Chief Medical Officer (CMO), effective immediately. Dr. Nguyen will be responsible for developing and leading the product portfolio vision and strategic direction for the Medical, Regulatory, Preclinical and Clinical Development, and Pharmacovigilance functions. He will report directly to John Shannon, Xeris’ CEO.
Dr. Nguyen succeeds Ken Johnson, PharmD, SVP, Global Development and Medical Affairs, who will retire on April 1, 2025. His return to Xeris is timed as the company prepares to embark on the Phase 3 development of XP-8121, a once-weekly subcutaneous injection for hypothyroidism, and continues to drive growth of its commercial portfolio, particularly Recorlev.
Dr. Nguyen brings extensive clinical and leadership experience, having previously served as the program medical lead for Gvoke’s NDA and MAA approvals during an earlier tenure at Xeris. His background includes leadership roles in developing first-in-class therapies and shaping clinical and regulatory policies at institutions such as the NIH, FDA, and CMS.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.